West Pharmaceutical Services Inc (NYSE: WST) has reported E.P.S. of $1.79 for its fourth fiscal quarter (ending December 31) versus $1.85 for the same period a year ago — a decline of -3%. However, this performance was $0.06 better than the consensus estimate of $1.73. For the latest four quarters through December 31, E.P.S. were $6.75 versus $7.98 for the same period a year ago — a decline of -15%.
Recent Price Action
West Pharmaceutical Services Inc (NYSE: WST) stock suffered a major decline of -38.2% on 2/13/25. The shares closed at $199.11. Moreover, exceptionally high trading volume at 890% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -40.6% during the last week.
Current PriceTarget Research Rating
West Pharmaceutical Services has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. West Pharmaceutical Services has a slightly negative Power Rating of 38 and a very low Appreciation Score of 14, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment